IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.6864
+0.0075 (1.10%)
At close: Dec 5, 2025, 4:00 PM EST
0.6826
-0.0038 (-0.55%)
After-hours: Dec 5, 2025, 6:21 PM EST
IceCure Medical Employees
As of December 31, 2024, IceCure Medical had 66 total employees, including 64 full-time and 2 part-time employees. The number of employees decreased by 11 or -14.29% compared to the previous year.
Employees
66
Change (1Y)
-11
Growth (1Y)
-14.29%
Revenue / Employee
$45,076
Profits / Employee
-$231,667
Market Cap
47.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | -11 | -14.29% |
| Dec 31, 2023 | 77 | 5 | 6.94% |
| Dec 31, 2022 | 72 | 8 | 12.50% |
| Dec 31, 2021 | 64 | 17 | 36.17% |
| Dec 31, 2020 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ICCM News
- 1 day ago - IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - PRNewsWire
- 17 days ago - IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 - PRNewsWire
- 18 days ago - IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - PRNewsWire
- 22 days ago - IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 24 days ago - IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 - PRNewsWire
- 26 days ago - IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction - PRNewsWire
- 4 weeks ago - IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival - PRNewsWire